Devices that are placed within fluid-filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.

The disclosure describes, in various example embodiments, a small arms or firearm projectile including a shell and a hemostatic material retained within the shell. The hemostatic material has a mechanical modulus above 25,000 Pa. In some embodiments, the shell includes a plurality of perforations. In some embodiments, the plurality of perforations are configured to provide, upon an impact of the projectile, fluid communication between the hemostatic material and the exterior of the shell via the plurality of perforations. In some embodiments, the hemostatic material includes a polymer core configured to provide a scaffold for inducing hemostasis in a local wound volume. In some embodiments, the projectile includes a contrasting agent. In some embodiments, the projectile includes a lubricating agent retained in the interior of the shell. In some embodiments, the projectile further includes 0.5 to 3 grains of Kaolin retained in the interior of the shell.

In some aspects, the present disclosure pertains to methods of treating a tissue volume comprising (a) administering an implantable composition comprising a releasable membrane-active agent to a target site such that the membrane-active agent is locally released to the tissue volume and (b) performing irreversible, reversible and/or thermal treatment by application of a pulsed electric field to the tissue volume. In other aspects, the present disclosure pertains to embolic compositions that comprise releasable membrane-active agents.

Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.

The present invention provides for compositions comprising a polymeric hydrogel impregnated with a toxin-absorbing or binding nanoparticle. The present invention also provides for the use of the above compositions for decreasing or neutralizing the effect of a toxin, or for treating or preventing an infection by a microbe that produces a toxin, in a subject. The exemplary toxin is a biological toxin such as a viral, bacterial, fungal, plant or animal toxin.

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

The invention relates to a composition that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent. It also relates to a liquid suspension that can be administered orally, comprising (a) opioid multi-particulates comprising an opioid active agent, and an abuse resistant release controlling agent; and/or (b) opioid antagonist multi-particulates comprising an opioid antagonist, and a release controlling agent and/or a release delaying agent; and wherein the multi-particulates are suspended in a liquid comprising a viscosity modifier and a flavoring agent. The invention also relates to kits containing these multi-particulates, and methods of making and using them.

Devices that are placed within fluid filled organs, such as the bladder, which reduce the risk of bacterial infections using a combination of active agents and mechanical disruption of bacteria.

The present invention relates in part a to multiparticulate sprinkle dosage form comprising duloxetine or a pharmaceutically acceptable salt thereof, having higher acid resistance as compared to commercially available delayed release formulations. It further relates to various methods of administering the said multiparticulate sprinkle dosage forms.

The present invention is in the field of manufacturing drug-loaded microparticles, and specifically provides processes for producing approximately homogenously sized drug loaded microparticles with high drug loading and reproducible drug release profiles, and which may be provided in a significantly reduced time period.